This Article Abstract Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (85) Citing Articles via Google Scholar Google Scholar Articles by Ray, K. K. Search for Related Content PubMed PubMed Citation Articles by Ray, K. K.

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Results From the PROVE IT-TIMI 22 Trial

Kausik K. Ray, MRCP, MD^_*, Christopher P. Cannon, MD, FACC^_*,_*, Carolyn H. McCabe, BS^_*, Richard Cairns, BSc, Andrew M. Tonkin, MD, Frank M. Sacks, MD, Graham Jackson, MD, FRCP^||, Eugene Braunwald, MD, MACC^_* for the PROVE IT-TIMI 22 Investigators

^_* TIMI Study Group, Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts
Nottingham Clinical Research Group, Nottingham, United Kingdom
Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Australia
Harvard School of Public Health, Boston, Massachusetts
^|| Guy’s Hospital, London, England

View larger version (23K): [in a new window]   Figure 1 Kaplan-Meier estimates of the composite end point of death, myocardial infarction (MI), and rehospitalization with recurrent acute coronary syndrome (ACS) by statin treatment. CI = confidence interval.

View larger version (14K): [in a new window]   Figure 2 (A) Cumulative hazard ratios (HRs) of the primary end point of death, myocardial infarction, unstable angina requiring hospitalization, urgent revascularization >30 days, and stroke showing the relative benefit as early as 15 days and achieving statistical significance by four months. (B) Cumulative HRs of composite triple end point of death, myocardial infarction, or rehospitalization with recurrent acute coronary syndrome showing the relative benefit as early as 15 days and achieving statistical significance by 30 days. CI = confidence interval.

View larger version (19K): [in a new window]   Figure 3 Kaplan-Meier estimates of the composite end point of death, myocardial infarction (MI), or rehospitalization with recurrent acute coronary syndrome (ACS) by statin treatment from randomization to 30 days. CI = confidence interval.

View larger version (12K): [in a new window]   Figure 4 (A) Conditional hazard ratios (HRs) for the primary end point in each year of the trial. (B) Conditional HRs for the composite triple end point in each year of the trial.

View larger version (19K): [in a new window]   Figure 5 Kaplan-Meier estimates of the composite end point of death, myocardial infarction (MI), or rehospitalization with recurrent acute coronary syndrome (ACS) by statin treatment, in patients free from clinical events from six months to end of study.